Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Open Access
- 9 August 2018
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 132 (6), 587-597
- https://doi.org/10.1182/blood-2018-03-840132
Abstract
Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including IDH1, IDH2, HUWE1, KLHL6, and PTPN11. Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and IRF4; t(14;16) with mutations in MAF, BRAF, DIS3, and ATM; and hyperdiploidy with gain 11q, mutations in FAM46C, and MYC rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.Keywords
This publication has 53 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsThe New England Journal of Medicine, 2011
- Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patientsBlood, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Egr1 mediates p53-independent c-Myc–induced apoptosis via a noncanonical ARF-dependent transcriptional mechanismProceedings of the National Academy of Sciences of the United States of America, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- IRF4 addiction in multiple myelomaNature, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002